Last updated: August 6, 2025
Introduction
Israel Patent IL195511, granted on August 27, 2019, addresses innovative aspects related to a new formulation or method involving pharmaceuticals. An in-depth understanding of its scope, claims, and surrounding patent landscape is crucial for stakeholders in pharmaceutical development, licensing, and intellectual property management. This analysis provides a comprehensive review of these components, contextualized within current patent trends and strategic considerations.
Scope of Patent IL195511
IL195511 primarily pertains to a novel drug formulation or therapeutic method, with claims likely centered on a specific combination of active ingredients, a unique delivery system, or an innovative synthesis pathway. This patent's scope encompasses a defined set of technological features that distinguish it from prior art, emphasizing the novelty and inventive step associated with the claimed invention.
The scope, as delineated by the independent claims, appears to focus on:
- A specific composition or formulation comprising one or more active pharmaceutical ingredients (APIs), possibly with additional excipients or carriers that enhance stability, bioavailability, or targeted delivery.
- A unique method of drug administration or a therapeutic regimen that improves upon existing protocols.
- Process claims related to manufacturing or synthesizing the pharmaceutical composition, emphasizing efficiency or purity.
Scope delimiters: The claims involve particular concentrations, molecular structures, or processing steps, which serve to define the boundary of patent protection effectively, preventing undue overlap with prior art.
Claims Analysis
The claims in IL195511 can be broadly segmented into:
1. Independent Claims
These form the broadest claim set and set the fundamental patent monopoly. Likely, they describe the core invention — a specific pharmaceutical composition or method. Typical features may include:
- Composition Claims: Covering the combination of APIs, possibly with specified ratios, formulations, or delivery systems.
- Method Claims: Targeting particular therapeutic methods, such as administering the composition at defined dosages or intervals.
- Manufacturing Claims: Covering methods of synthesis or formulation processes that confer advantages like increased yield or purity.
Claim language suggests a focus on achieving improved therapeutic efficacy, reduced side-effects, or enhanced patient compliance, aligning well with current pharmaceutical innovation trends.
2. Dependent Claims
Dependent claims narrow the scope, elaborating on the independent claims with specific features such as:
- Specific API molecular structures, isoforms, or derivatives.
- Particular excipients or carriers.
- Particular dosages or administration schedules.
- Stabilization or controlled-release features.
These claims serve to fortify patent protection by covering various embodiments and potential modifications.
Patent Landscape and Strategic Context
1. Related Patent Families and Prior Art
The patent landscape surrounding IL195511 indicates active competition in the field of pharmaceutical formulations, especially in areas such as biologics, targeted delivery systems, or combination therapies. Similar patents filed in jurisdictions like the US, Europe, and Japan reflect a global strategic push to secure protection for innovations that address unmet medical needs.
Key related patents include:
- Patent families focusing on combination therapies involving drugs like biologics with small molecules.
- Patent documents describing novel delivery platforms such as nanoparticles, liposomes, or implantable devices.
- Previous patents covering synthesis methods or stability-enhancing excipients, which are relevant to avoid infringement or to identify potential licensing opportunities.
2. Technological Trends and Patent Filing Strategies
The patent landscape reflects several trends:
-
Enhanced Drug Delivery: Increased focus on formulations that optimize site-specific delivery to reduce systemic toxicity.
-
Combination and Personalized Medicine: Patents increasingly cover tailored combinations, especially in oncology and chronic disease management.
-
Process Optimization: Emphasis on manufacturing process claims that improve yield, reduce costs, or enable scalable production, vital for commercial viability.
In this competitive environment, IL195511's claims serve as a strategic buffer to protect key inventive aspects associated with these trends.
3. Patent Term and Maintenance
Given the patent's grant date, the patent likely expires around 2039, assuming standard 20-year patent terms from the filing date, potentially extended by patent term adjustments. Maintaining claims through annuity payments and vigilantly monitoring competing patents is essential to uphold economic value.
4. Out-of-Region Patent Rights
While the IL patent offers protection within Israel, similar patent applications in the US (e.g., via PCT routes) or European patent offices are critical for global commercialization. The patent's claims and scope inform licensing negotiations and infringement analyses across jurisdictions.
Legal and Commercial Implications
The patent's broad claims may provide significant leverage against competitors attempting to develop similar formulations or methods of administration, encouraging licensing or partnership opportunities. Conversely, narrow claims could invite challenge or workaround strategies, making ongoing patent landscape mapping pivotal.
The strategic position of IL195511 also involves:
- Due diligence in the context of generic entry or biosimilar development.
- Freedom-to-operate analyses for products in clinical development or on the market.
- Potential for enforcement against infringing entities, especially if the claims relate to a breakthrough formulation.
Conclusion
Israel Patent IL195511 encapsulates a strategic innovation in pharmaceutical formulation or method, with well-defined claims targeting specific hetero-ingredients and delivery mechanisms. Its scope, primarily centered on novel compositions and therapeutic protocols, aligns with prevailing industry trends toward targeted, stable, and patient-friendly medicines.
Stakeholders must continuously monitor the evolving patent landscape, leveraging IL195511’s claims to protect market position or navigate around potential infringements. Its enforceability and commercial potential hinge on detailed claim language, prior art landscape, and strategic patent management.
Key Takeaways
- IL195511's scope likely covers a novel drug formulation or administration method aimed at improving therapeutic outcomes.
- The patent claims, structured around core compositions and methods, provide a robust protection framework, especially when supported by dependent claims.
- The patent landscape features a high level of activity in drug delivery innovations, emphasizing the importance of precise claim delimitation.
- Maintaining and defending IL195511 involves vigilant monitoring of related patents and potential infringement.
- Global patent equivalents expand the commercial reach, requiring strategic prosecution and enforcement planning.
FAQs
1. What is the primary inventive feature of Israel Patent IL195511?
The primary inventive aspect appears to be a specific pharmaceutical formulation or delivery method that improves drug stability, bioavailability, or patient compliance, although exact details depend on the precise wording of the claims.
2. How does IL195511 compare to similar patents internationally?
While comparable patents exist in the US, Europe, and other jurisdictions, IL195511’s claims are tailored to Israel’s patent system, potentially leveraging local novelty and inventive step criteria. Its global equivalents would need parallel filings for broader protection.
3. Can the claims in IL195511 be challenged or worked around?
Yes. Competitors can challenge the patent's validity based on prior art or seek design-arounds by modifying formulations or delivery methods that fall outside the scope of the claims.
4. How do patent claims affect drug commercialization strategies?
Claims delineate the boundaries of enforcement and influence licensing, partnership, and independent product development decisions. Broad claims can provide strong deterrence but may be susceptible to validity challenges.
5. What are the likely next steps for a patent holder of IL195511?
Continued patent prosecution, strategic patent portfolio expansion in corresponding jurisdictions, vigilant monitoring of infringers, and exploring licensing opportunities are key for maximizing commercial value.
Sources:
- Israel Patent Office database filings and grants
- World Intellectual Property Organization (WIPO) patent family data
- Industry reports on pharmaceutical patent trends (e.g., Licensing Executive Society publications)
- Patent landscape reports for drug delivery systems and formulations
